Publicité
La bourse est fermée

  • CAC 40

    8 167,50
    -20,99 (-0,26 %)
     

  • Euro Stoxx 50

    5 064,14
    -8,31 (-0,16 %)
     

  • Dow Jones

    40 003,59
    +134,19 (+0,34 %)
     

  • EUR/USD

    1,0872
    +0,0002 (+0,02 %)
     

  • Gold future

    2 419,80
    +34,30 (+1,44 %)
     

  • Bitcoin EUR

    61 430,70
    -45,74 (-0,07 %)
     

  • CMC Crypto 200

    1 360,24
    -13,60 (-0,99 %)
     

  • Pétrole WTI

    80,00
    +0,77 (+0,97 %)
     

  • DAX

    18 704,42
    -34,38 (-0,18 %)
     

  • FTSE 100

    8 420,26
    -18,39 (-0,22 %)
     

  • Nasdaq

    16 685,97
    -12,33 (-0,07 %)
     

  • S&P 500

    5 303,27
    +6,17 (+0,12 %)
     

  • Nikkei 225

    38 787,38
    -132,92 (-0,34 %)
     

  • HANG SENG

    19 553,61
    +177,11 (+0,91 %)
     

  • GBP/USD

    1,2706
    +0,0035 (+0,28 %)
     

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

Newsfile Corp.
·1 min de lecture

Encinitas, California--(Newsfile Corp. - May 8, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at The Citizens JMP Life Sciences Conference on Tuesday May 14th, 2024 at 1:00 pm EDT.

Kiora's presentations can be accessed live from the homepage of the investor relations section on Kiora's website (ir.kiorapharma.com) and will be available for replay for 90 days on the investor relations "events" page.

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

PUBLICITÉ

In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contacts:

Investors
investors@kiorapharma.com

Media
kiora@crowepr.com
Crowe PR

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/208302